Every Form 4 that IBEX Limited (IBEX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IBEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBEX filings page.
IBEX Ltd's Chief Financial Officer, Taylor C. Greenwald, reported equity compensation activity involving the company’s common shares. On February 6, 2026, the CFO acquired 20,000 common shares at $0 per share as a restricted stock award tied to a May 31, 2024 performance share grant based on revenue and EBITDA targets.
On the same date, 2,121 common shares were disposed of at $34.98 per share to cover tax withholding upon vesting. After these transactions, the CFO directly beneficially owned 54,361 common shares. One-third of the performance-based shares vested on February 6, 2026, with additional one‑third tranches scheduled to vest on February 6, 2027 and February 6, 2028, subject to continued service.
IBEX Ltd Chief AI & Digital Officer Michael Joseph Darwal reported several equity transactions. On February 11, 2026 he received a grant of 25,000 Restricted Stock Units, each representing one common share, vesting in four equal annual installments starting February 11, 2027, subject to continued service.
On February 6, 2026 he acquired 12,149 common shares at no cost upon vesting of an earlier performance share award tied to revenue and EBITDA targets, with additional thirds scheduled to vest on February 6, 2027 and February 6, 2028. That same day he sold 1,660 shares at $34.98 per share, described as shares withheld for tax purposes. After these transactions he directly owned 42,185 common shares.
IBEX Ltd Chief Executive Officer Robert Thomas Dechant reported equity compensation transactions in IBEX common shares. On February 6, 2026, he acquired 124,582 common shares at $0 as a restricted stock award tied to an April 20, 2022 performance share grant based on revenue and EBITDA targets.
One-third of this award vested on February 6, 2026, with additional thirds scheduled to vest on February 6, 2027 and February 6, 2028, subject to his continued service. On the same date, 18,988 shares were disposed of at $34.98 to cover taxes, leaving Dechant with 305,406 common shares held directly.
IBEX Ltd’s Chief Sales and CS Officer, Bruce Neil Dawson, reported equity awards and related tax withholding in company stock. On February 6, 2026, he acquired 82,519 common shares at $0 per share as a restricted stock award tied to an April 20, 2022 performance share grant that met revenue and EBITDA targets.
These shares vest in three equal parts: one-third vested on February 6, 2026, with additional thirds scheduled for February 6, 2027 and February 6, 2028, contingent on his continued service. On the same date, 12,246 common shares were disposed of at $34.98 per share to satisfy tax withholding on the vesting. After these transactions, he directly owned 77,034 common shares.
IBEX Ltd’s Chief People Officer, Inson Paul Joseph, reported equity compensation activity. On February 6, 2026, he acquired 25,180 IBEX common shares at $0 as a restricted stock award tied to an April 20, 2022 performance share grant based on revenue and EBITDA targets.
One-third of the award vested on February 6, 2026, with additional one‑third tranches scheduled for February 6, 2027 and February 6, 2028, subject to continued service. On the same date, 2,627 shares were sold at $34.98 to cover taxes upon vesting, leaving him with 27,469 common shares held directly.
IBEX Ltd reported an amended insider transaction. The company’s Chief Executive Officer and Director filed a Form 4/A to record the exercise of a stock option for 45,027 common shares at $19 on 09/16/2025 (transaction code M). The filing shows 0 derivative securities remaining afterward, indicating this option position was fully exercised.
The amendment explains that the acquisition and sale of the shares underlying this option were previously reported on September 17, 2025, and the option exercise itself was inadvertently omitted and is now included. The option was fully vested and exercisable, with an expiration date of 08/07/2030. Ownership is listed as Direct.
IBEX Ltd reported an insider equity award. The company’s Chief Technology Officer filed a Form 4 for a grant of 15,000 Restricted Stock Units (RSUs) on November 11, 2025. Each RSU converts into one common share. The filing lists the acquisition at $0 and shows 15,000 shares beneficially owned directly after the transaction.
The RSUs vest over four years: 3,750 units on November 11, 2026, with an additional 3,750 units vesting annually thereafter, subject to continued service.
On 09/30/2025 IBEX Ltd director and Chief People Officer Paul Joseph Inson had 2,347 performance-based stock units (PSUs) certified for the period ending 06/30/2025 and converted into 2,347 common shares. To satisfy tax withholding from that vesting, the reporting person sold 697 shares on 10/02/2025 at a weighted average price of $39.581, executed in multiple trades priced between $39.34 and $40.01. After these transactions the reporting person beneficially owned 4,916 common shares. The Form 4 states the sale was required to cover tax obligations and not a discretionary trade.
Christina Alice Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), had 3,228 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025. To satisfy tax-withholding obligations tied to that vesting, she sold 1,001 shares on 10/02/2025 at a weighted-average price of $39.5817, leaving her with 13,954 shares beneficially owned. The Form 4 states the PSUs were earned after certification of performance for the period ending 06/30/2025, and the reported sale was not a discretionary trade but a tax-withholding sale.
On September 30, 2025 IBEX Ltd director and Chief Sales and CS Officer Bruce Neil Dawson had 3,228 performance-based stock units (PSUs) certified as earned for the period ending June 30, 2025 and converted to common shares, bringing his total ownership to 7,720 shares following that acquisition. A subsequent sale on October 2, 2025 disposed of 959 shares at a weighted-average price of $39.5824, reducing his direct holdings to 6,761 shares.
The Form 4 states the 3,228 shares were acquired on vesting of performance awards and the 959 shares were sold solely to satisfy tax withholding obligations, not as discretionary trades. The filing discloses the sales executed in multiple trades at prices between $39.34 and $40.01.
Julie K. Casteel, Chief Sales/Marketing Officer of IBEX Ltd (IBEX), had 3,228 performance-based stock units vest and convert to common shares on 09/30/2025, increasing her holdings to 29,123 shares.
On 10/02/2025 she sold 806 shares at a weighted average price of $39.583 to satisfy tax-withholding obligations, leaving her with 28,317 beneficially owned shares. The filing states the PSU vesting followed certification of performance goals for the period ending 06/30/2025.
IBEX Ltd's Chief Operating Officer, David Martin Afdahl, had 3,228 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025 after certification of performance goals for the period ending 06/30/2025. To satisfy tax-withholding obligations related to that vesting, the reporting person sold 1,103 shares on 10/02/2025 at a weighted average price of $39.5818 per share. As a result of these transactions, the reporting person’s beneficial ownership declined from 58,214 shares following the PSU conversion to 57,111 shares after the sale. The Form 4 states the sales were required to cover taxes and were not discretionary trades.
IBEX Ltd insider report: Chief Financial Officer Taylor C. Greenwald had 4,196 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025, bringing total beneficial ownership to 37,757 shares.
On 10/02/2025 the reporting person sold 1,275 shares at a weighted average price of $39.5819 to satisfy tax withholding obligations related to the PSU vesting, leaving 36,482 shares beneficially owned. The Form 4 states the sales were not discretionary trades but were required to cover taxes; the filer offers to provide trade-level price details on request.
Robert Thomas Dechant, Chief Executive Officer and a director of IBEX Ltd (IBEX), had 14,524 performance-based stock units (PSUs) convert to common shares on September 30, 2025 after certification of performance goals for the period ending June 30, 2025. To satisfy tax-withholding obligations related to that vesting, 6,711 shares were sold in multiple trades on October 2, 2025 at a weighted average price of $39.5817 per share. Following these transactions, the reporting person beneficially owns 199,812 common shares.
IBEX Ltd (IBEX) reporting person Taylor C. Greenwald, Chief Financial Officer, sold 2,295 common shares on 09/19/2025 at $40.7302 per share. The Form 4 shows the sale was required to cover tax withholding for restricted stock units that vested and is not described as a discretionary trade. After the transaction the reporting person beneficially owned 33,561 shares, held directly. The filing was signed by an attorney-in-fact on 09/23/2025. No options, derivative transactions, or other compensatory arrangements are disclosed on this Form 4.